Valuation dashboard for NeuroPace, Inc. (NPCE) with P/E N/A, P/B 39.18, EV/EBITDA -43.63 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
Analysis Summary
NeuroPace, Inc. reported revenue of $100.0M in the most recent fiscal year, growing at a 5-year CAGR of 19.4%.
Trailing-twelve-month margins: gross margin 79.6%, operating margin -15.3%, net margin -19.3%.
At the current price of $14.10, NPCE has negative trailing earnings (P/E not meaningful) and an ROE of -119.68%. Market capitalisation stands at $481M.
Balance sheet quality for NPCE: current ratio of 5.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 39.18 |
| EV / EBITDA | -43.63 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NPCE | NeuroPace, Inc. | $481M | 39.18 | -119.7% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price
| Price | $14.10 |
| Market Cap | $481M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -119.68% |
| Return on Invested Capital | -18.43% |
| Return on Assets | -19.71% |
| Gross Margin | 79.63% |
| Operating Margin | -15.26% |
| Net Margin | -19.34% |
Related companies: ALDX · BWAY · CERS · CVRX · DCTH · GNLX · MASS
Explore sector: Healthcare · Medical - Devices
More sections of NPCE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks